The Emergence of COVID-19 to Augment Growth of the Endotracheal Tube Market

 

An Endotracheal Tube is a flexible plastic tube inserted into the trachea (windpipe) through the mouth to help a patient breathe. Then the tube is connected to a ventilator to deliver oxygen to the lungs. The process of inserting the tube is called endotracheal intubation. Endotracheal intubation is done to keep the airway open to give anesthesia, medicine, or oxygen. These tubes are widely used to support breathing in certain illnesses, such as severe trauma, collapsed lung, heart failure, emphysema, and pneumonia, as well as to remove blockages from the airway. The growth of the Endotracheal Tube Market is mainly driven by the emergence of COVID-19 (coronavirus) around the world.

COVID-19 is a respiratory disease and can cause a range of breathing problems, from mild to critical. According to the World Health Organization (WHO), worldwide, as of 3:57pm CEST, 27 April 2021, there have been around 147,539,302 confirmed cases of COVID-19, including 3,116,444 deaths. COVID-19 can affect the upper respiratory tract (sinuses, nose, and throat) and the lower respiratory tract (windpipe and lungs). Thus, there is an increasing demand for endotracheal tube due to increasing number of cases worldwide. For instance, in November 2020, GE Healthcare launched a new AI algorithm to help clinicians assess endotracheal tube placements, an important step when ventilating critically ill COVID-19 patients.

The AI solution is one of five included in GE Healthcare’s Critical Care Suite 2.01, an industry-first collection of algorithms embedded on a mobile x-ray device for automated measurements, case prioritization, and quality control. Moreover, the Endotracheal Tube Market growth can be attributed to the increasing prevalence of cardiovascular and respiratory diseases worldwide. According to the WHO, around 65 million people suffer from chronic obstructive pulmonary disease (COPD) and around 3 million die from it each year, making it the third leading cause of death worldwide. Around 334 million people suffer from asthma, the most common chronic disease of childhood affecting 14% of all children worldwide.

Furthermore, increasing number of surgical procedures, the growing prevalence of ventilator-associated pneumonia, and growing geriatric population with chronic and respiratory disease are some of major factors driving the Endotracheal Tube Market growth, especially in the Asia Pacific and North America. According to the WHO, the number of people aged 65 or older is projected to grow from an around 524 million in 2010 to nearly 1.5 billion in 2050. In January 2020, Smiths Medical launched a new Polyvinyl Chloride tracheostomy tube portfolio to its family of tracheostomy tubes. New tracheostomy tubes have options for a variety of patients.